- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
SPARC announced Ocuvex resubmitted the PDP-716 drug application to the US FDA. This addresses prior third-party manufacturing facility issues, not drug safety or efficacy concerns. It marks a key step towards potential market entry for the ophthalmic treatment.
All announcements from Sun Pharma Advanced Research Company Limited